TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05979987

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminder of preventive care measures
Description: The investigators will send randomized participants an SMS reminder encouraging them to click the provided link and close their outstanding, overdue preventive care measures.~The provided link will take them to their MyChart login page; after logging in, they would see their personalized My Action Plan Letter detailing their personalized, overdue preventive care measures.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminder of preventive care measures
Description: The investigators will send randomized participants an SMS reminder encouraging them to click the provided link and close their outstanding, overdue preventive care measures.~The provided link will take them to their MyChart login page; after logging in, they would see their personalized My Action Plan Letter detailing their personalized, overdue preventive care measures.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminder of preventive care measures
Description: The investigators will send randomized participants an SMS reminder encouraging them to click the provided link and close their outstanding, overdue preventive care measures.~The provided link will take them to their MyChart login page; after logging in, they would see their personalized My Action Plan Letter detailing their personalized, overdue preventive care measures.
Study: NCT04637594

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Given IV
Study: NCT05979987

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminder of preventive care measures
Description: The investigators will send randomized participants an SMS reminder encouraging them to click the provided link and close their outstanding, overdue preventive care measures.~The provided link will take them to their MyChart login page; after logging in, they would see their personalized My Action Plan Letter detailing their personalized, overdue preventive care measures.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Persuasion via anecdote
Description: The message will contain an anecdote of a patient whose cancer was caught early through similar, recommended preventive screenings. The message prompts patients to click on a link to read the story about the patient.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Persuasion via anecdote without link
Description: The message will contain a link to an anecdote of a patient whose cancer was caught early through similar, recommended preventive screenings. The message won't contain a link to the story, but it will briefly describe the story.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Persuasion via research
Description: This message will mention that research has shown promptly closing health gaps saves lives.The message will contain a link to an official website that supports the statement.
Study: NCT04546971

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Intervention
Description: Brief alcohol intervention delivered by telephone or videoconferencing focusing on advising participants to reduce drinking

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Intervention
Description: Brief alcohol intervention delivered by telephone or videoconferencing focusing on advising participants to reduce drinking

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth Counseling
Description: 5 sessions of counseling on alcohol use based on Motivational Interviewing.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text messaging
Description: A daily and then monthly text messaging program designed to help participants monitor drinking, set goals, and reinforce successful reduction or abstinence.
Study: NCT05716971

Intervention type: PROCEDURE
Intervention: Densiron-68 (heavy silicone oil) tamponade for retinal detachment
Description: pars plana vitrectomy using Densiron-68 at thee end of surgery

Intervention type: PROCEDURE
Intervention: Densiron-68 (heavy silicone oil) tamponade for retinal detachment
Description: pars plana vitrectomy using Densiron-68 at thee end of surgery
Study: NCT06113822

Intervention type: DEVICE
Intervention: ultrasonography
Description: We used ultrasonography to measure the patients' masseter muscle thickness. Measurements were performed simultaneously for both the right and left sides using a high frequency linear scanning probe (13-6 MHz) of an ultrasound device (Fujifilm Sonosite Edge II). In order to prevent possible artifacts and oblique imaging, the probe was kept perpendicular to the skin surface, and the distance between the location of the hyperechoic linear appearance of the mandibular and temporal bone in the transverse section and the muscular fascia were measured.

Intervention type: DEVICE
Intervention: ultrasonography
Description: We used ultrasonography to measure the patients' masseter muscle thickness. Measurements were performed simultaneously for both the right and left sides using a high frequency linear scanning probe (13-6 MHz) of an ultrasound device (Fujifilm Sonosite Edge II). In order to prevent possible artifacts and oblique imaging, the probe was kept perpendicular to the skin surface, and the distance between the location of the hyperechoic linear appearance of the mandibular and temporal bone in the transverse section and the muscular fascia were measured.
Study: NCT04637594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT04637594

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atezolizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Durvalumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avelumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Given IV
Study: NCT06342713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-45035
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-45035
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-45035
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-45035
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-45035
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-45035
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally
Study: NCT05742802

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Tozorakimab 1
Description: Participants randomised to either dose regimen in the predecessor studies will be assigned to a single Tozorakimab dose regimen in the PROSPERO study.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Tozorakimab 2
Description: Participants randomised to either dose regimen in the predecessor studies will be assigned to a single Tozorakimab dose regimen in the PROSPERO study.

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants previously randomised to placebo in one of the predecessor studies will be re-randomised in a 1:1 ratio to the active dose of Tozorakimab or placebo.
Study: NCT05360147

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: Liraglutide is a glucagon-like peptide type 1 (GLP-1) analogue. We had fond its cognitive improvement effects in an observational study. In order to confirm the effects, the investigators conduct a randomized, controlled study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral antidiabetic drugs: Metformin, Sulfonylureas (2nd generation), Thiazolidinediones, α-Glucosidase inhibitors, and Glinides
Description: oral antidiabetic drugs (OADs) or insulin, except for glucagon-like peptide type 1 (GLP-1) analogues
Study: NCT04933747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iberdomide
Description: Administration of a single oral dose of 1mg iberdomide in participants

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iberdomide
Description: Administration of a single oral dose of 1mg iberdomide in participants

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iberdomide
Description: Administration of a single oral dose of 1mg iberdomide in participants on 2 occasions - once on a dialysis day and once on a non-dialysis day
Study: NCT04871490

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Blood test for HPV DNA
Description: All participants will have blood tested for HPV DNA.
Study: NCT06578689

Intervention type: BEHAVIORAL
Intervention: Education
Description: The control group received standard care, while the intervention group received standard care supplemented with formal educational session followed by ongoing education on foot care using mobile health by a clinical pharmacist.
Study: NCT06576986

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Symbiotic
Description: The synbiotic used will be Simbioflora® (commercial preparation containing 5.5g of FOS added with four species of probiotic, Lactobacillus paracasei LPC-31; Lactobacillus rhamnosus HN001; Lactobacillus acidophilus NCFM; Bifidobacterium lactis HN019, at a concentration of 109 UFC per strain) supplied by Farmoquímica S.A. Supplementation will be administered orally, twice a day, before lunch and dinner, for ten days before chemotherapy treatment. Patients will be guided by researchers on dilution (100 mL of filtered water) and the correct purchase of the modules. Consumption control will be carried out daily, via telephone contact.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Symbiotic
Description: The synbiotic used will be Simbioflora® (commercial preparation containing 5.5g of FOS added with four species of probiotic, Lactobacillus paracasei LPC-31; Lactobacillus rhamnosus HN001; Lactobacillus acidophilus NCFM; Bifidobacterium lactis HN019, at a concentration of 109 UFC per strain) supplied by Farmoquímica S.A. Supplementation will be administered orally, twice a day, before lunch and dinner, for ten days before chemotherapy treatment. Patients will be guided by researchers on dilution (100 mL of filtered water) and the correct purchase of the modules. Consumption control will be carried out daily, via telephone contact.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Maltodextrin, used as control, will be purchased from the company PRODIET® under the trade name Carboch®. Supplementation will be administered orally, twice a day, before lunch and dinner, for ten days before chemotherapy treatment. Patients will be guided by researchers on dilution (100 mL of filtered water) and the correct purchase of the modules. Consumption control will be carried out daily, via telephone contact.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Maltodextrin, used as control, will be purchased from the company PRODIET® under the trade name Carboch®. Supplementation will be administered orally, twice a day, before lunch and dinner, for ten days before chemotherapy treatment. Patients will be guided by researchers on dilution (100 mL of filtered water) and the correct purchase of the modules. Consumption control will be carried out daily, via telephone contact.
Study: NCT06359821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZA-001
Description: Study drug ZA-001 administered via intravenous injection.
Study: NCT06538818

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultra Phonophoresis
Description: Therapeutic pulsed ultrasound using Phyaction UbMF ultrasound device in presence of a hyaluronic acid-containing gel will be applied gel pad over the wrist and along the course of median nerve at the carpal tunnel.~The following parameters will be used: intensity of 1.0 W/em2 at a 1MHz frequency for 5 minutes and pulsed (25%) ultrasound waves to transfer the hyaluronic acid-containing gel. This therapy will be applied for 5 min/session, 5 d/wk, for 3 weeks.~The following parameters will be used:~* intensity of 1.0 W/cm2~* 1MHz frequency~* pulsed (25%)~* 5 min/session, 5 d/wk, for 3 weeks.
Study: NCT06407115

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Description: CBT in this study will consist of a series of 6-10, 30-45-minute sessions with the care manager. These 1-on-1 sessions will occur every week or every other week virtually. Content will be focus on addressing unhelpful thinking and small behavioral changes that may help participants better manage their pain.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhance Fitness
Description: Participants will be encouraged to enroll in instructor-led exercises classes for up to an hour, 3 days per week. These classes can be accessed from home. Data plans and tablets are available to aid participants that need them to gain access to the classes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Care Coordination
Description: Care manager will meet with patient in virtual sessions once a month to create a care plan and monitor progress. Care manager will assess social determinants of health and link participants to resources in the community as appropriate. In addition, participants will take monthly assessments about pain and mood to help guide clinical decision making.
Study: NCT04751955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olinvacimab added to Capecitabine
Description: Olinvacimab: IV weekly administration In phase lb, 12mg/kg and 16mg/kg weekly IV will be tested. In phase ll, the RP2D in phase lb will be used. Capecitabine: fixed dose as an oral administration, 1250mg/m2 BID on day 1 to 14 followed by 7 days off
Study: NCT06175078

Intervention type: DEVICE
Intervention: Ultrasound Imaging 3D and Spectroscopy
Description: Ultrasound imaging and spectroscopy will consist of collecting three dimensional data. Regions of interest in each of the tumour images and in the adjacent normal tissue will be selected for analysis.
Study: NCT05540847

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interfascial Injection
Description: Interfascial Injection on Ultrasound-guided Obturator Nerve Block

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subpectineal Injection
Description: Subpectineal Injection on Ultrasound-guided Obturator Nerve Block
Study: NCT05056259

Intervention type: DEVICE
Intervention: 18F-FDG PET/CT
Description: The PET/CT procedure will be performed according to the institutional standard with 18F-FDG (0.8-1.2 mCi /kg) injection following 6 h fasting. Blood glucose was controlled to be \<150 mg/dl. PET/CT from the vertex to the middle femur will be obtained 60 min after FDG injection.~MDCT examination without IV contrast will be done for attenuation correction and anatomic localization followed by PET images from the skull vault to the mid-thigh region.~Images of CT and corresponding functional PET images are displayed in axial, coronal and sagittal planes.~PET/CT data will include tumor size and extension, LN invasion\& distant metastasis SUVmax will be calculated for all positive lesions, Metabolic parameters including SUVmax, SUVmean, TLG \& MTV will be calculated for primary tumor.~Data of PET will be compared with other diagnostic imaging and postoperative pathologic data.

Intervention type: DEVICE
Intervention: 18F-FDG PET/CT
Description: The PET/CT procedure will be performed according to the institutional standard with 18F-FDG (0.8-1.2 mCi /kg) injection following 6 h fasting. Blood glucose was controlled to be \<150 mg/dl. PET/CT from the vertex to the middle femur will be obtained 60 min after FDG injection.~MDCT examination without IV contrast will be done for attenuation correction and anatomic localization followed by PET images from the skull vault to the mid-thigh region.~Images of CT and corresponding functional PET images are displayed in axial, coronal and sagittal planes.~PET/CT data will include tumor size and extension, LN invasion\& distant metastasis SUVmax will be calculated for all positive lesions, Metabolic parameters including SUVmax, SUVmean, TLG \& MTV will be calculated for primary tumor.~Data of PET will be compared with other diagnostic imaging and postoperative pathologic data.
Study: NCT05831332

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BTL-785-7
Description: Treatment with the BTL-785F device with the BTL-785-7 applicator for non-invasive reduction of submental fat.
Study: NCT04267809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride
Description: Metformin 500mg tablets are registered and licensed in Singapore. For the study, we will be sourcing the Metformin tablets from Singapore General Hospital Formulary.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Calcium and Vitamin D
Description: Calcium and Vitamin D tablets are registered and licensed in Singapore. For the study, we will be sourcing the Calcium and Vitamin D tablets from Singapore General Hospital Formulary.
Study: NCT05854511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir 200 MG Oral Tablet plus Daclatasvir 30 mg Oral tablets
Description: Daclatasvir 30 mg orally once daily plus Sofosbuvir at a dose of 200 mg (2x 100 mg tablets) orally once daily for 12 weeks.
Study: NCT05704283

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound Imaging
Description: Undergo 3D-US
Study: NCT04827953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m2 IV on days 1, 8 and 15 (conventional chemotherapy).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: Nab-Paclitaxel 125 mg/m2 IV on days 1, 8 and 15 (conventional chemotherapy).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NLM-001
Description: NLM-001 will be administered three cycles consecutively followed by two rest cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zalifrelimab
Description: Zalifrelimab administration each 6 weeks.
Study: NCT04892329

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Artificial intelligence assistant system
Description: The endoscopists in the experimental group will be assisted by EndoAngel, which can assist in identifying important anatomical structures adjacent to the pancreas in real time. The system is an non-invasive AI system .
Study: NCT05688839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jaktinib hydrochloride tablets
Description: 2 doses per day, 100mg Jaktinib

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 2 doses per day, placebo
Study: NCT05693064

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: wait-list
Description: wait-list

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: chiropractic adjustments
Description: chiropractic adjustments
Study: NCT06272539

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The exercise The exercise will be adapted according to the phases based on the results already published, limiting in each phase the degrees of flexion and extension of the spine in order to avoid the risk of electrode migration.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Cord Stimulation
Description: Spinal cord stimulation (SCS) involves an implantable pulse generator with the potential for enhanced therapeutic success through stimulation algorithms and parameters (28). Spinal cord stimulation (SCS) targeting distal areas, such as the dorsal root ganglion, may offer greater anatomical specificity in therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulation
Description: Spinal cord stimulation (SCS) involves an implantable pulse generator with the potential for enhanced therapeutic success through stimulation algorithms and parameters (28). Spinal cord stimulation (SCS) targeting distal areas, such as the dorsal root ganglion, may offer greater anatomical specificity in therapy
Study: NCT05669417

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulfate
Description: Based on serum levels, bolus and or continuous administration is provided as dictated by study protocol.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Magnesium sulfate
Description: Based on serum levels, bolus and or continuous administration is provided as dictated by study protocol.
Study: NCT06550791

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anticancer Learning Circle
Description: All participants will partake in the Anticancer Learning Circle, a lifestyle modification program. All participants will complete web-based learning modules focused on improving diet, lowering stress, increasing fitness, and reducing exposure to toxins in the home environment. Each week, all participants will meet as a group to discuss the learning topic of the web-based learning module for the week.
Study: NCT04494490

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Practice Guidelines and Psychologically Informed Physical Therapy training/audit/feedback
Description: The aim of the active training strategy is to improve the knowledge and skills of physical therapists with regard to evidence-based physical therapy with an emphasis on active treatments and PIPT for the treatment of patients with low back pain and to encourage increased adherence with CPGs. This Continuing Education (CE) training session will be offered to all therapists regardless of study participation. During the CE training session, focus will be placed on interventions that have been shown to be effective, such as interactive education and discussion, feedback, and reminders.